Company profile
Alibion AG
Our goal is to bring to the market the first oral, personalized therapy against Rheumatoid arthritis. We are developing the first drug potentially capable of reversing inflammation and bone erosion in a very well defined population of patients.
Source: startup.ch
More news about Alibion AG
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
